Guardant Health/$GH
1D1W1MYTD1Y5YMAX
Capital at risk
About Guardant Health
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
- Ticker
- $GH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,498
- Headquarters
- Palo Alto, United States
- Website
- guardanthealth.com
Guardant Health Metrics
BasicAdvanced
$24B
-
-$3.50
1.59
-
Price and volume
Market cap
$24B
Beta
1.59
52-week high
$183.51
52-week low
$55.38
Average daily volume
2M
Financial strength
Current ratio
4.026
Quick ratio
3.533
Long term debt to equity
-7.49
Total debt to equity
-7.614
Interest coverage (TTM)
-97.39%
Profitability
EBITDA (TTM)
-430.571
Gross margin (TTM)
65.01%
Net profit margin (TTM)
-38.33%
Operating margin (TTM)
-39.74%
Effective tax rate (TTM)
0.23%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-18.12%
Return on equity (TTM)
171.64%
Valuation
Price to revenue (TTM)
19.622
Price to book
-107.54
Price to tangible book (TTM)
-73.66
Price to free cash flow (TTM)
-96.436
Free cash flow yield (TTM)
-1.04%
Free cash flow per share (TTM)
-1.86
Growth
Revenue change (TTM)
42.74%
Earnings per share change (TTM)
4.74%
3-year revenue growth (CAGR)
32.36%
3-year earnings per share growth (CAGR)
-10.47%
What the Analysts think about Guardant Health
Analyst ratings (Buy, Hold, Sell) for Guardant Health stock.
Analyst projections of the future price of Guardant Health stock.
Bulls say / Bears say
Guardant Health’s Q2 2026 revenue rose 44 % year-over-year to $335 million, topping the $314.23 million consensus and prompting management to raise its full-year 2026 revenue guidance to $1.34 billion–$1.36 billion (Reuters)
On June 11 2026 the FDA approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS in HER2-mutant NSCLC, expanding its clinical utility and potential test volume (FT)
Updated American Cancer Society guidelines now include Guardant’s Shield blood test as a recommended screening option for individuals who forgo traditional tests, potentially unlocking access to over 50 million unscreened Americans (Reuters)
A recent Delaware federal court verdict orders Guardant Health to pay over $245.2 million in damages plus a 6 % royalty on sales of 11 core tests, significantly increasing future legal liabilities and cost pressure (Reuters)
GH’s shares have surged roughly 272 % over the past year, reflecting a potentially overstretched valuation and heightened risk of a market correction (Reuters)
Management reaffirmed a cash flow breakeven target only by end-2027, underscoring a prolonged path to profitability amid rising operating expenses (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 28 Aug 2026.
Guardant Health Financial Performance
Revenues and expenses
Guardant Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Guardant Health News
AllArticlesVideos
Guardant Health's Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Business Wire6 days ago
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
Business Wire2 weeks ago
Business Insider Names Guardant Health One of America's Most Innovative Businesses
Business Wire2 weeks ago
Funds containing Guardant Health
AllUSDEURGBP
Fund name | Fund size | $GH weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.73% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.73% |
iShares Healthcare Innovation£DRDR | £1B | 1.73% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.60% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.60% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.